Merrill Lynch is excited by Azilect, and has upgraded its recommendation for Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) to "Buy" from "Neutral" following ADAGIO study, which indicates that Azilect could be the first product shown to slow the progression of Parkinson’s disease. Merrill Lynch also raised its target price to $54 from $50 based on higher Azilect sales and a modestly higher multiple. Teva closed at $44.73 on Nasdaq yesterday.
My board friends are investing in miniature startup medical research companies. They say that the upside is tremendous. One good product and they are extreemely profitable. Maybe TEVA is still such a company? I dont own TEVA.
2 comments:
POST SCRIPTUM
I AM AN IDIOT
I DID NOT BUY THEN
They have just in-licenced an interesting new drug for multiple sclerosis.
Post a Comment